title: Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.
abstract: Exacerbations of chronic obstructive pulmonary disease (COPD) have important consequences for lung function, health status and mortality. Furthermore, they are associated with high economic costs, predominantly related to hospitalization. They are managed acutely with short-acting bronchodilators, systemic corticosteroids or antibiotics; however, a large proportion of COPD exacerbations are unreported and therefore untreated or self-managed. There is evidence to suggest that these unreported exacerbations also have important consequences for health status; therefore, reducing exacerbation risk is an important goal in the management of COPD. Current guidelines recommend long-acting muscarinic antagonists (LAMAs) as first-line bronchodilator therapy in patients with stable COPD who have a high risk of exacerbation or increased symptoms. To date, three LAMAs, tiotropium bromide, aclidinium bromide and glycopyrronium bromide, have been approved as maintenance bronchodilator treatments for stable COPD. These all provide clinically significant improvements in lung function, reduce symptoms and improve health status compared with placebo in patients with COPD. This paper reviews evidence from randomized, controlled clinical trials demonstrating that tiotropium, aclidinium and glycopyrronium reduce exacerbation risk in patients with COPD. Reductions were seen irrespective of the exacerbation measure used, whether time to first event or annualized exacerbation rate. Furthermore, studies with aclidinium suggest LAMAs can reduce exacerbation risk irrespective of whether exacerbation events are assessed, using an event-based approach or a symptom-based method which includes unreported events. Together these results demonstrate that LAMAs have the potential to provide clinical benefit in the management of exacerbations in patients with stable COPD.
authors: St George's, University of London, Cranmer Terrace, London SW17 0RE, UK pjones@sgul.ac.uk.
authors: Paul W
authors: PW
authors: Jones
mesh_terms: D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D006024:Glycopyrrolate / Q000627:therapeutic use; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D000069447:Tiotropium Bromide / Q000627:therapeutic use; D014326:Tropanes / Q000627:therapeutic use
chemical_list: D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D014326:Tropanes; C542859:aclidinium bromide; D006024:Glycopyrrolate; D000069447:Tiotropium Bromide
keywords: COPD; LAMA; aclidinium; exacerbations; glycopyrronium; tiotropium